Om

Obsidian Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on engineered cell and gene therapies for cancer, with an emphasis on solid tumors. The company develops tumor-infiltrating lymphocyte (TIL) therapies built on its proprietary cytoDRiVE platform, which is designed to control protein function using FDA-approved small-molecule drugs. Its lead program, OBX-115, is an investigational autologous TIL therapy incorporating membrane-bound IL15 to support T-cell activity, persistence, and antitumor response. Obsidian Therapeutics’ current pipeline centers on next-generation immuno-oncology treatments for advanced melanoma, non-small cell lung cancer, and other solid tumor indications. The company operates within the biotechnology sector, where its platform-based approach combines cell engineering, protein regulation, and clinical development to address difficult-to-treat cancers.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I OBSIDIAN THERAPEUTICS MED ENDAVU: Køb Obsidian Therapeutics ($OBX) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Obsidian Therapeutics, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.